source
- Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head testThe results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.BioPharma Dive · 1mo ago↗ source
- Opinion: We published in Nature Medicine in 2025 for free. In 2026, it cost us $12,850In 2025, Elizabeth Selvin and her colleagues published in Nature Medicine for free. In 2026, it cost them $12,850, she writes.STAT · 1mo ago↗ source
- Opinion: How long Covid’s scientific stalemate made it politically erasableLong Covid hasn’t disappeared. It’s just gone underground, writes Steven Phillips.STAT · 1mo ago↗ source